Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT06092255
Other study ID # SZGBMRT001
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date March 1, 2022
Est. completion date December 30, 2025

Study information

Verified date October 2023
Source Jiangsu Cancer Institute & Hospital
Contact Lining Guo
Phone 15182456673
Email guolining2023@163.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This phase I/II clinical trial is intended to investigate the efficacy and safety of SVZ irradiation with postoperative radiotherapy in patients with GBM.


Description:

This study is a single-center, single-arm, phase I/II clinical study. It is intended to include treatment-naïve patients with histologically or cytologically confirmed glioblastoma who have received only radical surgical treatment according to the investigator's assessment. After signing the informed consent, the patient will be selected to meet the inclusion criteria and will receive postoperative adjuvant radiotherapy combined with temozolomide chemotherapy, followed by 6 cycles of temozolomide maintenance therapy. During the follow-up process, patients included in the study can withdraw from this study if they are judged by MRI examination to have disease progression, unacceptable toxic reactions occur, or the subject decides to withdraw from the study. The subsequent specific treatment plan will be discussed with the MDT and fully discussed with the patient and family members. Implement after communication.


Recruitment information / eligibility

Status Recruiting
Enrollment 40
Est. completion date December 30, 2025
Est. primary completion date December 30, 2024
Accepts healthy volunteers No
Gender All
Age group 18 Years to 70 Years
Eligibility Inclusion Criteria: 1. Patients voluntarily join this study, have the ability to understand and are willing to sign the informed consent form. 2. Aged between 18-70 years old (inclusive). 3. Newly diagnosed glioblastoma confirmed by pathology. 4. The patient must have undergone maximum surgical resection and start radiotherapy within 12 weeks after surgery. 5. MRI shows that the patient's SVZ area is involved or the distance between the tumor and the SVZ area is less than or equal to 1cm. 6. No previous brain irradiation. 7. Women of childbearing age have a negative urine test or serum pregnancy test and are contraceptive during the treatment period. 8. The ECOG performance status assessed within 7 days before the study intervention is 0-1 points. 9. Have sufficient organ function, and the subject needs to meet the following laboratory indicators: 1. Absolute neutrophil count (ANC) =1.5x109/L without using granulocyte colony-stimulating factor in the past 14 days. 2. Without blood transfusion in the past 14 days, platelets are =80×109/L. 3. Without blood transfusion or erythropoietin use in the past 14 days, hemoglobin =9g/dL (90g/L) or =5.6mmol/L. 4. Total bilirubin =1.5×upper limit of normal (ULN); or total bilirubin >1.5×ULN but direct bilirubin =SULN. 5. aspartate aminotransferase (AST), alanine aminotransferase (ALT) =2.5×ULN, or subjects with liver metastasis =5× ULN. 6. Serum creatinine = 1.5 × ULN and creatinine clearance (calculated using the Cockcroft-Gault formula) = 60 ml/min. 7. Good coagulation function: International normalized ratio (INR) or prothrombin time (PT) = 1.5 times ULN; or the subject is receiving anticoagulant therapy but the prothrombin time (PT) or partial thromboplastin time (PTT) is within the therapeutic range for the anticoagulant's intended use; • Activated partial thromboplastin time (aPTT) ) or partial thromboplastin time (PTT) =1.5 times ULN; or the subject is receiving anticoagulant therapy, but the prothrombin time (PT) or activated partial thromboplastin time (PTT) is below the expected use of the anticoagulant Within the therapeutic range; 8. Normal thyroid function, defined as thyroid stimulating hormone (TSH) within the normal range. If the baseline TSH is outside the normal range, subjects can also be enrolled if total T3 (or FT3) and FT4 are within the normal range. 9. myocardial enzyme spectrum is within the normal range (such as a simple experiment that is not clinically significant in the comprehensive judgment of the researcher). Ventricular abnormalities are also allowed to be included); simple laboratory abnormalities are also allowed to be included). Exclusion Criteria: 1. Have a personal history of malignant tumors within two years. 2. Use anti-vascular drugs such as bevacizumab before progression. 3. Women who are pregnant or breastfeeding, and women of childbearing age who are unwilling or unable to accept birth control methods during the entire study period and up to 12 weeks after the study. 4. Physical examination or clinical experimental findings that the researcher believes may interfere with the results or increase the patient's risk of treatment complications. 5. Unstable systemic accompanying diseases (active infection stage, moderate to severe chronic obstructive pulmonary disease, poorly controlled high blood pressure) Blood pressure disease, unstable angina, congestive heart failure, myocardial infarction within 6 months, severe mental disorder requiring drug control, liver, kidney or other metabolic diseases, neuropsychiatric changes such as Alzheimer's disease). 6. There may be other medical history or disease evidence that may interfere with the trial results, prevent the subject from fully participating in the study, abnormal treatment or laboratory test values, or other conditions that the researcher believes are not suitable for enrollment. The researcher believes that there are other potential risks and are not suitable for participation. this research. allowed to join the group).

Study Design


Related Conditions & MeSH terms


Intervention

Radiation:
Postoperative radiotherapy for SVZ
GBM patients who met the inclusion criteria received radiotherapy range and dose based on the EORTC outline principles. The ipsilateral and contralateral SVZ areas received 56Gy and 40Gy respectively, with a fractionated dose of 2Gy. Concurrent chemotherapy with temozolomide and six cycles of adjuvant temozolomide chemotherapy were performed at the same time as radiotherapy.

Locations

Country Name City State
China Lining Guo Nanjing Jiangsu

Sponsors (1)

Lead Sponsor Collaborator
Jiangsu Cancer Institute & Hospital

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Primary PFS Progression-free survival (PFS), defined as the time from treatment to progression or death, whichever occurs first; 12 monnths
Secondary OS Overall survival (OS), defined as the time from treatment to death. 12 monnths
Secondary Safety evaluation Adverse events were assessed according to NCI CTCAE (version 5.0) 12 months
See also
  Status Clinical Trial Phase
Recruiting NCT06147505 - Natural Killer (NK) Cells (XS005) Injection Combined With Stupp Regimen for Adjuvant Chemotherapy in Subjects With Primary Glioblastoma(GBM) Phase 1/Phase 2
Recruiting NCT05076513 - Trial of Niraparib in Participants With Newly-diagnosed Glioblastoma and Recurrent Glioma Early Phase 1
Recruiting NCT04528680 - Ultrasound-based Blood-brain Barrier Opening and Albumin-bound Paclitaxel and Carboplatin for Recurrent Glioblastoma Phase 1/Phase 2
Terminated NCT03149575 - VAL-083 Phase 3 Study in Temozolomide-Avastin (Bevacizumab) Recurrent GBM Phase 3
Completed NCT01478178 - Safety Study of VAL-083 in Patients With Recurrent Malignant Glioma Phase 1/Phase 2
Terminated NCT03119064 - BrUOG 329 Onivyde & Metronomic Temozolomide in Recurrent Glioblastoma Phase 1/Phase 2
Recruiting NCT05686798 - Adenovirus Mediated Suicide Gene Therapy With Radiotherapy in Progressive Astrocytoma. Phase 1
Recruiting NCT03758014 - Studies of Chlorogenic Acid for Injection for Safety and Efficacy of Grade IV GBM Patients Phase 2/Phase 3
Terminated NCT01205334 - Administration of CMV-Specific Cytotoxic T Cells in Patients With Glioblastoma Multiforme Phase 1/Phase 2
Active, not recruiting NCT00114309 - 131-I-TM-601 Study in Adults With Recurrent High-Grade Glioma Phase 2
Not yet recruiting NCT03746288 - To Evaluate the Efficacy and Safety of CAN008 Combined With Re-irradiation (rRT) for Treating Patients With Recurrent Glioblastoma (GBM) Phase 2
Terminated NCT04681677 - Recurrent GBM Treated With Neurosurgical Resection and IORT Using the Xoft Axxent eBx System and Bevacizumab Phase 2
Completed NCT01856933 - BrUOG 263: Prostate Specific Membrane Antigen (PSMA) Glioblastoma Multiforme (GBM) Phase 2
Terminated NCT04763031 - Recurrent GBM With Maximal Neurosurgical Removal and Treatment With IORT N/A
Completed NCT00107003 - GW572016 to Treat Recurrent Malignant Brain Tumors Phase 2
Completed NCT03426891 - Pembrolizumab and Vorinostat Combined With Temozolomide for Newly Diagnosed Glioblastoma Phase 1
Recruiting NCT04115761 - Evaluate the Efficacy and Safety of ADCV01 as an Add-On Treatment for Primary Glioblastoma Multiforme (GBM) Patients Phase 2
Recruiting NCT05954858 - Surgical Tissue Flap to Bypass the Blood Brain Barrier in Glioblastoma N/A
Not yet recruiting NCT06388733 - A Study Comparing Niraparib With Temozolomide in Adult Participants With Newly-diagnosed, MGMT Unmethylated Glioblastoma Phase 3
Recruiting NCT02861898 - Super-selective Intra-arterial Repeated Infusion of Cetuximab for the Treatment of Newly Diagnosed Glioblastoma Phase 1/Phase 2